Same Indication

Montelukast vs Nivolumab

Montelukast vs Nivolumab: Overview

This comparison examines the pharmacological differences between Montelukast and Nivolumab.

Mechanism of Action

Montelukast: Selective leukotriene D4 receptor antagonist.

Nivolumab: Fully human anti-PD-1 IgG4 monoclonal antibody restoring T-cell anti-tumor activity.

Pharmacokinetics

Half-life: Montelukast — 2.7-5.5 hours; Nivolumab — 27 days.

Chemical Properties

Molecular Formula: Montelukast — C35H36ClNO3S.

Molecular Weight: Montelukast — 586.1800 g/mol.

Type: Montelukast — Small molecule; Nivolumab — Antibody.